A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients

British Journal of Cancer

Volumn 90, Issue 5, 2004, Pages 985-990

  Bleumer, I ^a   Knuth, A ^b   Oosterwijk, E ^a   Hofmann, R ^c   Varga, Z ^c   Lamers, C ^d   Kruit, W ^d   Melchior, S ^e   Mala, C ^f   Ullrich, S ^f   De Mulder, P ^a   Mulders, P F A ^a   Beck, J ^e  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Northwest Hospital   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f Wilex Biotechnology GmbH   (Germany)

Author keywords

CA IX; Immunotherapy; Monoclonal antibody; Renal cell carcinoma; WX G250

Indexed keywords

CHIMERIC ANTIBODY; MONOCLONAL ANTIBODY G250; UNCLASSIFIED DRUG;

ADULT; AGED; ALLERGY; ARTICLE; BLEEDING; BLOOD TOXICITY; BONE MARROW TOXICITY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; EYE TOXICITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; KIDNEY CARCINOMA; LIVER TOXICITY; LUNG TOXICITY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; NEPHROTOXICITY; NEUROTOXICITY; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 11144354471     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601617     Document Type: Article

References (20)

1. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6: 443-446
2. Escudier B, Chevreau C, Lasset C, Douillard JY, Ravaud A, Fabbro M, Caty A, Rossi JF, Viens P, Bergerat JP, Savary J, Negrier S (1999) Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Francais d'Immunotherape. J Clin Oncol 17: 2039-2043
3. Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, Klotz LH, Moore MJ, Paton V, Bajamonde A (1998) Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 338: 1265-1271
4. Grabmaier K, Vissers JL, De Weijert MC, Oosterwijk-Wakka JC, Van Bokhoven A, Brakenhoff RH, Noessner E, Mulders PA, Merkx G, Figdor CG, Adema GJ, Oosterwijk E (2000) Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 85: 865-870
5. Lamers HJ, Gratama JW, van Putten WL, Stoter G, Bolhuis RL (1991) Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes. Cancer Res 51: 2324-2328
6. Lissoni P, Barni S, Ardizzoia A, Crispino S, Paolorossi F, Andres M, Scardino E, Tancini G (1994) Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma. Oncology 51: 59-62
7. Liu Z, Smyth FE, Renner C, Lee FT, Oosterwijk E, Scott AM (2002) Antirenal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother 51: 171-177
8. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825-2833
9. Medical Research Counsil (1999) Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353: 14-17
10. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20: 289-296
11. Mulders P, Figlin R, DeKernion JB, Wiltrout R, Linehan M, Parkinson D, deWolf W, Belldegrun A (1997) Renal cell carcinoma: recent progress and future directions. Cancer Res 57: 5189-5195
12. Nathan PD, Eisen TG (2002) The biological treatment of renal-cell carcinoma and melanoma. Lancet Oncol 3: 89-96
13. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 338: 1272-1278
14. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, Pauwels EK, Jonas U, Zwartendijk J, Warnaar SO (1986) Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 38: 489-494
15. Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, De Vries IJ, Jongmans W, Adema GJ, Debruyne FM, De Mulder PH, Oosterwijk E, Mulders PF (2002) Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother 25: 500-508
16. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, Oosterhof GO, Witjes JA, Koenders EB, Oyen WJ, Buijs WC, Debruyne FM, Corstens FH, Oosterwijk E (1997) Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 15: 1529-1537
17. Surfus JE, Hank JA, Oosterwijk E, Welt S, Lindstrom MJ, Albertini MR, Schiller JH, Sondel PM (1996) Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J Immunother Emphasis Tumor Immunol 19: 184-191
18. Uemura H, Okajima E, Debruyne FM, Oosterwijk E (1994) Internal image anti-idiotype antibodies related to renal-cell carcinoma-associated antigen G250. Int J Cancer 56: 609-614
19. Vance BA, Huizinga TW, Wardwell K, Guyre PM (1993) Binding of monomeric human IgG defines an expression polymorphism of Fc gamma RIII on large granular lymphocyte/natural killer cells. J Immunol 151: 6429-6439
20. Wiseman GA, Scott AM, Lee FT, Gansen W, Hopkins W, Steinmetz S, Ingle JN, Croghan GA, Barch PA, Davis I, Moynihan TJ, Warnaar S, Ullrich S, Mason L, Pugliese L, Digvi C, Hoffman E, Old L (2001) Chimeric G250 (WX-G250) monoclonal antibody phase I dose escalation trial in patients with advanced renal cell carcinoma. Proc Natl Acad Sci USA (abstract)